Horm Metab Res 2019; 51(06): 347-352
DOI: 10.1055/a-0887-6213
Endocrine Care
© Georg Thieme Verlag KG Stuttgart · New York

Long-Term Variations of Antithyroperoxidase Antibodies and its Clinical Significance

Masoumeh Keyhanian*
1   Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, I. R. Iran
,
Farzaneh Sarvghadi*
1   Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, I. R. Iran
,
Ladan Mehran
1   Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, I. R. Iran
,
Atieh Amouzegar
1   Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, I. R. Iran
,
Maani Beigy
1   Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, I. R. Iran
,
Maryam Tohidi
2   Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, I. R. Iran
,
Fereidoun Azizi
1   Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, I. R. Iran
› Author Affiliations
Further Information

Publication History

received 15 August 2018

accepted 27 March 2019

Publication Date:
17 June 2019 (online)

Abstract

Various cut-offs have been proposed for thyroid peroxidase antibodies (TPOAb) positivity. Considering that the long-term trend of TPOAb levels and its positivity incidence is not clearly understood, we conducted the current study to determine the longitudinal variations of TPOAb in a population-based cohort study. We followed 5783 individuals of Tehran Thyroid cohort Study (TTS) for 10 years (4 phases). After exclusions, data of 3493 euthyroid participants remained for analyses. The baseline prevalence rates of TPOAb positivity were 19.8, 17, and 11.4% and the annual incidence rates (95% CI) of TPOAb positivity were 8.53 (8.29–8.77), 7.59 (7.37–7.80) and 6.79 (6.60–6.98) per 1000 persons for the 3 proposed cut-offs of 14.77, 18.38, and 40 U/l; respectively. Although a slightly increasing trend was observed for TPOAb levels (p=0.001) and its conventional positivity (TPOAb>40U/l), the recently proposed cut-offs of 14.77 and 18.38 U/l showed constant TPOAb positivity over 10 years. The time trends of the TPOAb levels among younger participants were significantly different from older participants (time×age effect p=0.004), with the former having an increasing trend and the latter, a relatively decreasing trend. Although the prevalence of TPOAb positivity was significantly (p<0.001) higher among women as compared to men, the longitudinal changes of TPOAb were similar in men and women. TPOAb positivity along with TSH values between 2.5 and 5.0 mU/l or free T4 values between 0.93 and 1.7 ng/dl exerted a significantly increased risk of subclinical or overt hypothyroidism. In an iodine sufficient population, an increasing trend in TPOAb levels was observed in line with the increasing incidence of subclinical and overt hypothyroidism.

* KM and SF are co-first authors as they contributed equally to this manuscript.


Supplementary Material

 
  • References

  • 1 Lee HJ, Li CW, Hammerstad SS. et al. Immunogenetics of autoimmune thyroid diseases: A comprehensive review. J Autoimmun 2015; 64: 82-90
  • 2 Bahn Chair RS, Burch HB, Cooper DS. et al. Hyperthyroidism and other causes of thyrotoxicosis: Management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid 2011; 21: 593-646
  • 3 Williamson S, Greene SA. Incidence of thyrotoxicosis in childhood: A national population based study in the UK and Ireland. Clin Endocrinol (Oxf) 2010; 72: 358-363
  • 4 Hetzel BS. Iodine deficiency disorders (IDD) and their eradication. Lancet 1983; 2: 1126-1129
  • 5 Saranac L, Zivanovic S, Bjelakovic B. et al. Why is the thyroid so prone to autoimmune disease?. Horm Res Paediatr 2011; 75: 157-165
  • 6 Devereaux D, Tewelde SZ. Hyperthyroidism and thyrotoxicosis. Emerg Med Clin North Am 2014; 32: 277-292
  • 7 Mariotti S, Caturegli P, Piccolo P. et al. Antithyroid peroxidase autoantibodies in thyroid diseases. J Clin Endocrinol Metab 1990; 71: 661-669
  • 8 Baloch Z, Carayon P, Conte-Devolx B. et al. Laboratory medicine practice guidelines. Thyroid 2003; 13: 3-126
  • 9 Amouzegar A, Bakhtiyari M, Mansournia MA. et al. Sex and age specific reference values and cut-off points for TPOAb: Tehran Thyroid Study (TTS). Thyroid 2016; 26: 458-465
  • 10 Vanderpump MP, Tunbridge WM, French JM. et al. The incidence of thyroid disorders in the community: A twenty-year follow-up of the Whickham Survey. Clin Endocrinol (Oxf) 1995; 43: 55-68
  • 11 Hollowell JG, Staehling NW, Flanders WD. et al. Serum TSH, T4, and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002; 87: 489-499
  • 12 Li Y, Teng D, Shan Z. et al. Antithyroperoxidase and antithyroglobulin antibodies in a 5-year follow-up survey of populations with different iodine intakes. J Clin Endocrinol Metab 2008; 93: 1751-1757
  • 13 Walsh JP, Bremner AP, Feddema P. et al. Thyrotropin and thyroid antibodies as predictors of hypothyroidism: A 13-year, longitudinal study of a community-based cohort using current immunoassay techniques. J Clin Endocrinol Metab 2010; 95: 1095-1104
  • 14 Amouzegar A, Delshad H, Mehran L. et al. Reference limit of thyrotropin (TSH) and free thyroxine (FT4) in thyroperoxidase positive and negative subjects: A population based study. J Endocrinol Investigat 2013; 36: 950-954
  • 15 Amouzegar A, Beigy M, Gharibzadeh S. et al. Underestimation of Thyroid dysfunction risk due to regression dilution bias in a long-term follow-up: Tehran thyroid study (TTS). Horm Metab Res 2014; 46: 440
  • 16 LeFevre ML. Screening for thyroid dysfunction: US Preventive services task force recommendation statement. Annals of internal medicine 2015; 162: 641-650
  • 17 Azizi F, Mehran L, Sheikholeslam R. et al. Sustainability of a well-monitored salt iodization program in Iran: Marked reduction in goiter prevalence and eventual normalization of urinary iodine concentrations without alteration in iodine content of salt. J Endocrinol Invest 2008; 31: 422-431
  • 18 Azizi F, Amouzegar A, Delshad H. et al. Natural course of thyroid disease profile in a population in nutrition transition: Tehran thyroid study. Arch Iran Med 2013; 16: 418-423
  • 19 Azizi F, Ghanbarian A, Momenan AA. et al. Prevention of non-communicable disease in a population in nutrition transition: Tehran lipid and glucose study phase II. Trials 2009; 10: 5
  • 20 Azizi F, Amouzegar A, Delshad H. et al. Natural course of thyroid disease profile in a population in nutrition transition: Tehran Thyroid Study. Arch Iran Med 2013; 16: 418
  • 21 Gardner DG, Shoback DM. Greenspan’s basic and clinical endocrinology: McGraw-Hill Medical. China 2011
  • 22 O'Leary PC, Feddema PH, Michelangeli VP. et al. Investigations of thyroid hormones and antibodies based on a community health survey: The Busselton thyroid study. Clin Endocrinol 2006; 64: 97-104
  • 23 Amouzegar A, Delshad H, Mehran L. et al. Reference limit of thyrotropin (TSH) and free thyroxine (FT4) in thyroperoxidase positive and negative subjects: A population based study. J Endocrinol Invest 2013; 36: 950-954
  • 24 Pedersen IB, Laurberg P, Knudsen N. et al. Smoking is negatively associated with the presence of thyroglobulin autoantibody and to a lesser degree with thyroid peroxidase autoantibody in serum: A population study. Eur J Endocrinol 2008; 158: 367-373
  • 25 Belin RM, Astor BC, Powe NR. et al. Smoke exposure is associated with a lower prevalence of serum thyroid autoantibodies and thyrotropin concentration elevation and a higher prevalence of mild thyrotropin concentration suppression in the third National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2004; 89: 6077-6086
  • 26 Rose NR, Bonita R, Burek CL. Iodine: An environmental trigger of thyroiditis. Autoimmun Rev 2002; 1: 97-103
  • 27 Li HS, Jiang HY, Carayanniotis G. Modifying effects of iodine on the immunogenicity of thyroglobulin peptides. J Autoimmun 2007; 28: 171-176
  • 28 Tomer Y, Huber A. The etiology of autoimmune thyroid disease: a story of genes and environment. J Autoimmun 2009; 32: 231-239
  • 29 Wiersinga WM. Thyroid autoimmunity. Endocr Dev 2014; 26: 139-157
  • 30 van de Ven AC, Netea-Maier RT, Ross HA. et al. Longitudinal trends in thyroid function in relation to iodine intake: Ongoing changes of thyroid function despite adequate current iodine status. Eur J Endocrinol 2014; 170: 49-54
  • 31 Boss GR, Seegmiller JE. Age-related physiological changes and their clinical significance. Western Journal of Medicine 1981; 135: 434
  • 32 Rowe JW, Andres R, Tobin JD. et al. The effect of age on creatinine clearance in men: a cross-sectional and longitudinal study. J Gerontol 1976; 31: 155-163
  • 33 Mariotti S, Chiovato L, Franceschi C. et al. Thyroid autoimmunity and aging. Exp Gerontol 1998; 33: 535-541
  • 34 Aghini Lombardi F, Fiore E, Tonacchera M. et al. The effect of voluntary iodine prophylaxis in a small rural community: The Pescopagano survey 15 years later. J Clin Endocrinol Metab 2013; 98: 1031-1039
  • 35 Pedersen IB, Knudsen N, Carle A. et al. A cautious iodization programme bringing iodine intake to a low recommended level is associated with an increase in the prevalence of thyroid autoantibodies in the population. Clin Endocrinol (Oxf) 2011; 75: 120-126
  • 36 Shan Z, Chen L, Lian X. et al. Iodine status and prevalence of thyroid disorders after introduction of mandatory universal salt iodization for 16 years in China: A cross-sectional study in 10 cities. Thyroid 2016; 26: 1125-1130
  • 37 Eschler DC, Hasham A, Tomer Y. Cutting edge: The etiology of autoimmune thyroid diseases. Clin Rev Allergy Immunol 2011; 41: 190-197
  • 38 Teng W, Shan Z, Teng X. et al. Effect of iodine intake on thyroid diseases in China. N Engl J Med 2006; 354: 2783-2793
  • 39 Doufas AG, Mastorakos G, Chatziioannou S. et al. The predominant form of non-toxic goiter in Greece is now autoimmune thyroiditis. Eur J Endocrinol 1999; 140: 505-511
  • 40 Kahaly GJ, Dienes HP, Beyer J, Hommel G. Iodide induces thyroid autoimmunity in patients with endemic goitre: a randomised, double-blind, placebo-controlled trial. Eur J Endocrinol 1998; 139: 290-297
  • 41 Burek CL, Talor MV. Environmental triggers of autoimmune thyroiditis. J Autoimmun 2009; 33: 183-189
  • 42 Hollowell JG, Staehling NW, Hannon WH. et al. Iodine nutrition in the United States. Trends and public health implications: Iodine excretion data from National Health and Nutrition Examination Surveys I and III (1971–1974 and 1988–1994). J Clin Endocrinol Metab 1998; 83: 3401-3408